Once-Daily Therapy with Ceftriaxone Compared with Daily Multiple-Dose Therapy with Cefotaxime for Serious Bacterial Infections: A Randomized, Double-Blind Study
Autor: | Robin Van, Thomas J. Marrie, Raphael Saginur, Ronald Feld, Raymond Duperval, Lilly J Miedzinski, Donald E. Low, Carlos Vega, Allan R. Ronald, Lionel A. Mandell, James L. Brunton, Michel G. Bergeron, Godfrey K. M. Harding, Stephan J. Landis, Richard G. Lalonde |
---|---|
Rok vydání: | 1989 |
Předmět: |
Adult
Male medicine.medical_specialty Cefotaxime medicine.drug_class medicine.medical_treatment Antibiotics Gram-Positive Bacteria Drug Administration Schedule law.invention Random Allocation Double-Blind Method Randomized controlled trial law Internal medicine Gram-Negative Bacteria medicine Humans Multicenter Studies as Topic Immunology and Allergy Aged Clinical Trials as Topic Chemotherapy business.industry Ceftriaxone Bacterial Infections Middle Aged medicine.disease Surgery Clinical trial Infectious Diseases Bacteremia Toxicity Female business medicine.drug |
Zdroj: | Journal of Infectious Diseases. 160:433-441 |
ISSN: | 1537-6613 0022-1899 |
Popis: | A randomized, double-blind study was done to compare the efficacy and toxicity of daily single-dose therapy with intravenous ceftriaxone (2 g every 24 h) with daily multiple-dose therapy with cefotaxime (2 g every 6 h) for treatment of serious bacterial infections in nonneutropenic patients. Of the 325 patients who were evaluable for toxicity, 241 (74.2%) were evaluable for efficacy. Infection sites included lung (106), urinary tract (42), skin and soft tissue (43), bone and joint (23), bacteremia (21), and hepatobiliary (5). Definite infections were present in 173 cases (71.8%) and possible infections in 68 (28.2%). Analysis of clinical and bacteriologic responses and adverse drug reactions showed no significant differences between the regimens. Values for 95% confidence limits on the differences between regimens for positive clinical and bacteriological outcomes in definite infections were -0.8% to 3.0% and -1.9% to 9.1%, respectively. Thus, daily single-dose therapy with ceftriaxone was comparable to daily multiple-dose therapy with cefotaxime in treating these bacterial infections. |
Databáze: | OpenAIRE |
Externí odkaz: |